BioSpace News Archive

OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved OPKO’s 4Kscore Test.

Hoth Therapeutics, Inc. is pleased to announce that it has entered into an agreement with Zylö Therapeutics (“Zylö”) to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö.

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer Platform, announced that it has been awarded a second ‘Direct to Phase 2’ Small Business Innovation Research grant from the National Cancer Institute.

Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing ™ Technology as New Category in Genetic Medicine.

Actinium Pharmaceuticals, Inc. announced today its participation in the Targeted Radiopharmaceuticals Summit being held virtually December 7 – 9, 2021.

Nanoscope Therapeutics Inc announced today the company’s Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Michael Singer, M.D., a member of Nanoscope’s Clinical Advisory Board, at Stanford University’s Innovate Retina summit on December 11, 2021.

Jasper Therapeutics, Inc. (NASDAQ: JSPR), today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.